Patent application number | Description | Published |
20100041162 | USE OF ARYLBORONIC ACIDS IN PROTEIN LABELLING - The present invention relates to the tagging of Histidine in polypeptides with arylboronic acid tagging reagents. The present invention further describes methods and devices to identify proteins in a sample by isolating and identifying Histidine-comprising peptides from one protein sample or a pool of protein samples. The present invention further describes databases of Histidine-comprising peptides from in silico cleaved proteins and their use in the identification of proteins. | 02-18-2010 |
20100068819 | COMPOUNDS AND METHODS FOR DOUBLE LABELLING OF POLYPEPTIDES TO ALLOW MULTIPLEXING IN MASS SPECTROMETRIC ANALYSIS - The present invention describes double labelling reagents with both an isotopic and isobaric label component suitable for differentially labelling different—protein samples. After labelling of the individual protein samples, all samples are pooled. Peptides from the pooled samples are isolated and analysed by mass spectrometry for determining the relative concentration of each differentially double-labelled polypeptide. | 03-18-2010 |
20100190183 | PROTEIN LABELLING WITH TAGS COMPRISING ISOTOPE-CODED SUB-TAGS AND ISOBARIC SUB-TAGS - Subject of the present invention are new isotopic and isobaric tagged molecules, kits comprising them and methods of using them in mass spectrometry. | 07-29-2010 |
20100215581 | CONTRAST AGENTS FOR DETECTING PROSTATE CANCER - The invention relates to contrast agents for diagnosing prostate cancer in a human or animal being. These contrast agents are compounds comprising a targeting module that is capable of interacting with a prostate cancer-specific molecular marker and a detectable unit. The invention also concerns the use of such compounds for diagnosing prostate cancer in a human or animal being. | 08-26-2010 |
20100304493 | SELECTIVE ENRICHMENT OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND/OR PEPTIDES FROM COMPLEX SAMPLES - The present invention relates to the selective enrichment of post-translationally modified proteins and/or peptides from complex samples by combining a particular protein/peptide labeling and fractionation strategy with specific chemical and/or enzymatic reactions targeting the post-translational modification to be analyzed. More specifically, the invention relates to methods for the enrichment and/or separation of phospho-proteins and/or -peptides, and particularly for the discrimination between different subsets of phospho-proteins and/or -peptides in complex samples. | 12-02-2010 |
20100311115 | SELECTIVE ENRICHMENT OF POST-TRANSLATIONALLY MODIFIED PROTEINS - The present invention relates to the selective enrichment of post-translationally modified proteins and/or peptides from complex samples. In particular, the invention relates to methods for the separation of phospho-proteins and/or -peptides and/or for the discrimination between different subsets of phospho-proteins and/or -peptides. | 12-09-2010 |
20110028330 | COMPOUNDS AND METHODS FOR THE LABELLING AND AFFINITY-SELECTION OF PROTEINS - The present invention relates to kits and methods for the isotopic/isobaric labeling and the subsequent affinity selection and analysis of proteinaceous molecules. In particular, the invention relates to a kit-of-parts comprising a combinatorial plurality of labeling reagent for the labeling of proteinaceous molecules, each labeling reagent comprising an isobaric label component, an isotopic label component, and a reactive group capable of reacting with a proteinaceous molecule, wherein the isotopic label component concomitantly is an affinity tag. The invention is also directed to a corresponding method for the analysis of proteinaceous molecules, comprising labeling at least one subset of the proteinaceous molecules present by employing a kit-of-parts as defined herein and subsequently separating the labeled molecules by affinity purification via the affinity tag comprised in the label. Finally, the invention relates to the uses of such methods for protein expression profiling or proteomic analyses. | 02-03-2011 |
20110045989 | SELECTIVE ENRICHMENT OF N-TERMINALLY MODIFIED PEPTIDES FROM COMPLEX SAMPLES - The present invention relates to methods allowing the selective enrichment of N-terminal fragments of polypeptides and/or peptides from complex samples by combining a particular polypeptide/peptide labeling and fractionation strategy with specific chemical and/or enzymatic reactions targeting the N-terminal fragments to be analyzed. | 02-24-2011 |
20120065100 | PHOSPHODIESTERASE 9A AS PROSTATE CANCER MARKER - The present invention relates to phosphodiesterase 9A (PDE9A) for use as a marker for prostate cancer, and the use of PDE9A as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of prostate cancer, in particular hormone-resistant prostate cancer. | 03-15-2012 |
20120065148 | PHOSPHODIESTERASE 4D7 AS PROSTATE CANCER MARKER - The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer, as well as a pharmaceutical composition comprising a compound directly stimulating or modulating the activity of PDE4D7, a compound indirectly stimulating or modulating the activity of PDE4D7, the PDE4D7 protein or a biologically active equivalent thereof, a nucleic acid encoding and expressing PDE4D7, a miRNA inhibitor specific for PDE4D7 miRNAs, a demethylation agent and/or a phosphodiesterase displacement factor. | 03-15-2012 |
20120129788 | PHOSPHODIESTERASE 4D7 AS MARKER FOR MALIGNANT, HORMONE-SENSITIVE PROSTATE CANCER - The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive prostate cancer. | 05-24-2012 |
20140156200 | ASSESSMENT OF CELLULAR SIGNALING PATHWAY ACTIVITY USING PROBABILISTIC MODELING OF TARGET GENE EXPRESSION - The present application mainly relates to specific methods for inferring activity of one or more cellular signaling pathway(s) in tissue of a medical subject based at least on the expression level(s) of one or more target gene(s) of the cellular signaling pathway(s) measured in an extracted sample of the tissue of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods. | 06-05-2014 |